Document Type : Review articles


1 Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Behavioral Sciences Research Center, Lifestyle Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

3 Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran


Context: The prevalence of in-hospital death due to COVID-19 hospital is one of the qualitative indexes, which can be used to assess the quality of care, as well as the mortality patterns in COVID-19 pandemic.Objectives: Therefore, this study has been done with the goal of estimating overall prevalence in-hospital death due to COVID-19 disease in iranian patients.Evidence Acquisition: Articles were identified through iranian searching databases including Health.barakatkns, IranDoc, SID, Civilica and MagIran and international searching databases including Scopus, Web of Science, PubMed and Elsevier . Additional search was also done by Google Scholar search engine. We reviewed systematically all studies reporting the prevalence of in-hospital death due to COVID-19 disease. In this study meta-analysis method with random effect model has been used to estimate the pooled in-hospital death.Results: 118 records were identified by the electronic search, of which 43 studies were identified as relevant documents that were meta-analyzed for the pooled in-hospital death due to COVID-19 prevalence. Overall, prevalence of death were 12.16% (95% CI: 10.72%-13.61%). The highest and lowest death prevalence has been reported in Northern Provinces (Gilan, 27.27% (95% CI: 8.66%-45.88%) and Mazandaran, 21.27% (95% CI: 18.14%-24.40%)) and Turkish-speaking provinces (Azerbaijan, East, 3.29% (95% CI: 2.11%-4.47%) and Zanjan, 3.42% (95% CI: 1.82%-5.02%)) respectively.Conclusions: Considering the death rate obtained in this study and its comparison with other countries, it can be said that the performance of the Iranian medical system in COVID-19 pandemic is acceptable.


  1. WHO. WHO characterizes COVID-19 as a pandemic. 2020; Available from:
  2. Grech, V., Unknown unknowns - COVID-19 and potential global mortality. Early human development, 2020. 144: p. 105026-105026.
  3. WHO. Coronavirus disease (COVID-19) pandemic. 2020 2020-12-01]; Available from:
  4. Al-Dorzi, H.M., S. Alsolamy, and Y.M. Arabi, Critically ill patients with Middle East respiratory syndrome coronavirus infection. Crit Care, 2016. 20(65): p. 016-1234.
  5. Tadbiri, H., M. Moradi-Lakeh, and M. Naghavi, All-cause excess mortality and COVID-19-related deaths in Iran. Medical Journal of The Islamic Republic of Iran (MJIRI), 2020. 34(1): p. 561-566.
  6. Goldstein, N.D. and I. Burstyn, On the importance of early testing even when imperfect in a pandemic such as COVID-19. Global epidemiology, 2020. 2: p. 100031-100031.
  7. Kandel, N., et al., Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries. Lancet (London, England), 2020. 395(10229): p. 1047-1053.
  8. Ding, Z.Y., et al., Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol, 2020.
  9. Yan, X., et al., Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. J Med Virol, 2020. 92(11): p. 2573-2581.
  10. Asch, D.A., et al., Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic. JAMA Intern Med, 2020.
  11. Goodman, K.E., et al., Impact of Sex and Metabolic Comorbidities on COVID-19 Mortality Risk Across Age Groups: 66,646 Inpatients Across 613 U.S. Hospitals. Clin Infect Dis, 2020.
  12. Izurieta, H.S., et al., Natural history of COVID-19: Risk factors for hospitalizations and deaths among >26 million U.S. Medicare beneficiaries. J Infect Dis, 2020.
  13. Mallow, P.J., et al., Outcomes of Hospitalized COVID-19 Patients by Risk Factors: Results from a United States Hospital Claims Database. J Health Econ Outcomes Res, 2020. 7(2): p. 165-174.
  14. Macedo, M.C.F., et al., Correlation between hospitalized patients' demographics, symptoms, comorbidities, and COVID-19 pandemic in Bahia, Brazil. PLoS One, 2020. 15(12): p. e0243966.
  15. Núñez-Gil, I.J.J., et al., Underlying heart diseases and acute COVID-19 outcomes. Cardiol J, 2020.
  16. Rubio-Rivas, M., et al., Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. J Clin Med, 2020. 9(11).
  17. Rodilla, E., et al., Impact of arterial stiffness on all-cause mortality in patients hospitalized with COVID-19 in Spain. Hypertension, 2020.
  18. Piroth, L., et al., Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med, 2020.
  19. Zeitoun, J.D., M. Faron, and J.H. Lefèvre, Impact of the local care environment and social characteristics on aggregated hospital fatality rate from COVID-19 in France: a nationwide observational study. Public Health, 2020. 189: p. 104-109.
  20. Ferroni, E., et al., Survival of Hospitalized COVID-19 Patients in Northern Italy: A Population-Based Cohort Study by the ITA-COVID-19 Network. Clin Epidemiol, 2020. 12: p. 1337-1346.
  21. Abate, S.M., Y.A. Checkol, and B. Mantefardo, Global prevalence and determinants of mortality among patients with COVID-19: A systematic review and meta-analysis. Annals of medicine and surgery (2012), 2021. 64: p. 102204-102204.
  22. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020. 395(10223): p. 497-506.
  23. Guo, Y.-R., et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status. Military Medical Research, 2020. 7(1): p. 1-10.
  24. Shi, H., et al., Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases, 2020. 20(4): p. 425-434.
  25. Moher, D., et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev.[Internet]. 2015; 4: 1.
  26. Chinazzi, M., et al., The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science, 2020. 368(6489): p. 395-400.
  27. Gostic, K., et al., Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. Elife, 2020. 24(9): p. 55570.
  28. Nicola, M., et al., The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg, 2020. 78: p. 185-193.
  29. Moftakhar, L., et al., Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients. Int J Diabetes Dev Ctries, 2021. 9: p. 1-6.
  30. Rastad, H., et al., The risk factors associated with COVID-19-Related death among patients with end‐stage renal disease. Bmc Nephrology, 2021. 22(1).
  31. Rastad, H., et al., Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. Diabetology & Metabolic Syndrome, 2020. 12(1).
  32. Rastad, H., et al., Factors associated with the poor outcomes in diabetic patients with COVID-19. Journal of Diabetes and Metabolic Disorders, 2020. 19(2): p. 1293-1302.
  33. Javanian, M., et al., Risk factors for mortality of 557 adult patients with COVID 19 in Babol, Northern Iran: a retrospective cohort study. Bratisl Lek Listy, 2021. 122(1): p. 34-38.
  34. Javanian, M., et al., Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study. Rom J Intern Med, 2020: p. 161-167.
  35. Mohammadi, F., et al., Artificial neural network and logistic regression modelling to characterize COVID-19 infected patients in local areas of Iran. Biomedical Journal, 2021.
  36. Takhti, H.K., et al., Symptoms and factors associated with the hospitalization period of 3480 Covid-19 patients in Hormozgan, Iran. 2021.
  37. Sami, R., et al., A one-year hospital-based prospective COVID- 19 open-cohort in the Eastern Mediterranean region: The Khorshid COVID Cohort (KCC) study. PLoS One, 2020. 15(11 November).
  38. Janani, M., et al., Epidemiological features and hotspot of COVID-19 in Isfahan province of Iran: Results of a cohort study. 2020.
  39. Sayad, B., et al., Leukocytosis and alteration of hemoglobin level in patients with severe COVID‐19: Association of leukocytosis with mortality. Health science reports, 2020. 3(4).
  40. Moradi, E.V., et al., Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. American Journal of Emergency Medicine, 2021. 40: p. 11-14.
  41. Sobhani, S., et al., Association between Clinical Characteristics and Laboratory Findings with Outcome of Hospitalized COVID-19 Patients: A Report from Northeast Iran. Interdisciplinary perspectives on infectious diseases, 2021. 2021.
  42. Nasiri, M., et al., The probable association between blood groups and prognosis of covid-19. Iranian Journal of Public Health, 2021. 50(4): p. 825-830.
  43. Rashidi, F., et al., Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. Thrombosis Research, 2021. 198: p. 135-138.
  44. Hormati, A., et al., Clinical characteristics and Mortality risk factors among COVID-19 patients in Qom–Iran; The results of a Retrospective Cohort study. 2020.
  45. Monfared, A., et al., Clinical characteristics and outcome of COVID-19 pneumonia in kidney transplant recipients in Razi hospital, Rasht, Iran. Transpl Infect Dis, 2020. 22(6): p. 2.
  46. Araban, M., et al., Epidemiological, clinical characteristics of coronavirus-infected disease (COVID-19) among sample of Iranian community: funding from survey in central of Iran. 2020.
  47. Peymani, P., et al., Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients. Transl Med Commun, 2021. 6(1): p. 021-00082.
  48. Shahriarirad, R., et al., Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. BMC Infectious Diseases, 2020. 20(1): p. 1-12.
  49. Alamdari, N.M., et al., Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku Journal of Experimental Medicine, 2020. 252(1): p. 73-84.
  50. Baghaei, P., et al., Clinical manifestations of patients with coronavirus disease 2019 (Covid-19) in a referral center in iran. Tanaffos, 2020. 19(2): p. 122-128.
  51. Bikdeli, B., et al., Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thrombosis Research, 2020. 196: p. 382-394.
  52. Kashefizadeh, A., et al., Clinical features and short-term outcomes covid-19 in tehran, iran: An analysis of mortality and hospital stay. Acta Biomedica, 2020. 91(4): p. 1-10.
  53. Pirsalehi, A., et al., Neutrophil-to-lymphocyte ratio (NLR) greater than 6.5 May reflect the progression of COVID-19 towards an unfavorable clinical outcome. Iranian Journal of Microbiology, 2020. 12(5): p. 466-474.
  54. Sabri, A., et al., Novel coronavirus disease 2019: Predicting prognosis with a computed tomography-based disease severity score and clinical laboratory data. Polish Archives of Internal Medicine, 2020. 130(7-8): p. 629-634.
  55. Soleimani, A., et al., Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19. American Journal of Hypertension, 2020. 33(12): p. 1102-1111.
  56. Zali, A., et al., Baseline Characteristics and Associated Factors of Mortality in COVID-19 Patients; an Analysis of 16000 Cases in Tehran, Iran. Arch Acad Emerg Med, 2020. 8(1).
  57. Homayounieh, F., et al., Clinical and imaging features predict mortality in COVID-19 infection in Iran. PLoS One, 2020. 15(9).
  58. Maghbooli, Z., et al., Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PLoS One, 2020. 15(9 September).
  59. Looha, M.A., et al., Assessing Sex Differential in COVID-19 Mortality Rate by Age and Polymerase Chain Reaction Test Results; An Iranian Multi-Center Study. 2021.
  60. Aghaaliakbari, F., et al., Angiotensin Converting Enzyme Inhibitors, A Risk Factor of Poor Outcome in Diabetic Patients with COVID-19 Infection. Iranian journal of kidney diseases, 2020. 14(6).
  61. Pazoki, M., et al., Risk indicators associated with in-hospital mortality and severity in patients with diabetes mellitus and confirmed or clinically suspected COVID-19. Journal of Diabetes & Metabolic Disorders, 2021: p. 1-11.
  62. Khoshnood, R.J., et al., Epidemiological Characteristics, Clinical Features, and Outcome of COVID-19 Patients in Northern Tehran, Iran; a Cross-Sectional Study. Advanced Journal of Emergency Medicine, 2020.
  63. Mousavi, S.A., et al., Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study. Hematology, 2020. 25(1): p. 383-388.
  64. Kalantari, H., A.H.H. Tabrizi, and F. Foroohi, Determination of COVID-19 prevalence with regards to age range of patients referring to the hospitals located in western Tehran, Iran. Gene Reports, 2020. 21: p. 100910.
  65. Akbariqomi, M., et al., Clinical characteristics and outcome of hospitalized COVID-19 patients with diabetes: A single-center, retrospective study in Iran. diabetes research and clinical practice, 2020. 169: p. 108467.
  66. Nikpouraghdam, M., et al., Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. Journal of Clinical Virology, 2020. 127: p. 104378.
  67. Allameh, S.F., et al., Clinical Characteristics and Outcomes of 905 COVID-19 Patients Admitted to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran. Archives of Iranian Medicine, 2020. 23(11): p. 766-775.
  68. Papizadeh, S., et al., Epidemiologic and clinical characteristics of 186 hospitalized patients with Covid-19 in Tehran, Iran: A retrospective, single-center case series. 2020.
  69. Vahedian-Azimi, A., et al., The Primary Outcomes and Epidemiological and Clinical Features of Coronavirus Disease 2019 (COVID-19) in Iran. Adv Exp Med Biol, 2021: p. 199-210.
  70. Gharebaghi, N., et al., Evaluation of epidemiology, clinical features, prognosis, diagnosis and treatment outcomes of patients with COVID-19 in West Azerbaijan Province. International Journal of Clinical Practice, 2021: p. e14108.
  71. Rokni, M., et al., Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness. BMC Infectious Diseases, 2020. 20(1).